Motif Neurotech
Healthcare · Biotech
Motif Neurotech Secures FDA IDE for Brain Implant TRD Trial
April 27, 2026
Motif Neurotech received FDA Investigational Device Exemption approval for its RESONATE early feasibility study of the XCS System, a wireless brain implant targeting treatment-resistant depression. The milestone, achieved four years post-founding, enables safety evaluation across eight institutions.
Read the Full Story in Velocity
Get curated startup and tech news with new stories published daily, company insights, and real-time alerts.